Tempus AI (NASDAQ:TEM) Receives Sell (D-) Rating from Weiss Ratings

Tempus AI (NASDAQ:TEM)‘s stock had its “sell (d-)” rating reissued by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other equities analysts also recently weighed in on TEM. BTIG Research raised their target price on shares of Tempus AI from $75.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, August 20th. Bank of America raised their target price on shares of Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, June 25th. Piper Sandler restated a “neutral” rating on shares of Tempus AI in a report on Friday, August 8th. Morgan Stanley lifted their price target on shares of Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, August 12th. Finally, HC Wainwright lifted their price target on shares of Tempus AI from $90.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $71.83.

Tempus AI Stock Performance

NASDAQ:TEM opened at $103.25 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. The firm has a 50-day moving average price of $77.21 and a two-hundred day moving average price of $64.16. Tempus AI has a twelve month low of $31.36 and a twelve month high of $103.42. The company has a market capitalization of $17.94 billion, a P/E ratio of -86.76 and a beta of 4.87.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. During the same period last year, the firm posted ($6.86) EPS. The firm’s revenue for the quarter was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. As a group, research analysts expect that Tempus AI will post -6.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In related news, COO Ryan Fukushima sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $92.32, for a total value of $461,600.00. Following the completion of the sale, the chief operating officer directly owned 130,000 shares in the company, valued at approximately $12,001,600. The trade was a 3.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James William Rogers sold 7,528 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the sale, the chief financial officer owned 138,473 shares of the company’s stock, valued at approximately $10,337,009.45. The trade was a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 933,662 shares of company stock valued at $68,070,993. Corporate insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently bought and sold shares of the stock. Concord Wealth Partners lifted its position in Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after buying an additional 308 shares in the last quarter. GAMMA Investing LLC acquired a new position in Tempus AI during the third quarter valued at approximately $28,000. Allworth Financial LP lifted its position in Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. Cherry Tree Wealth Management LLC acquired a new position in Tempus AI during the first quarter valued at approximately $31,000. Finally, SouthState Corp lifted its position in Tempus AI by 3,761.5% during the second quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after buying an additional 489 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.